The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oncology Immunotherapy Market Research Report 2025

Global Oncology Immunotherapy Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1721985

No of Pages : 75

Synopsis
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global Oncology Immunotherapy market was valued at US$ 2251 million in 2023 and is anticipated to reach US$ 3807.5 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
The Oncology Immunotherapy market has expanded as a groundbreaking approach to treating cancer by harnessing the body's immune system to target and fight cancer cells. This innovative therapy includes immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, among others. By enhancing the immune response against tumors, immunotherapy offers potentially durable and targeted treatments, often with fewer side effects compared to traditional approaches. The market's growth is driven by promising clinical outcomes and a growing understanding of immune-tumor interactions. As researchers continue to explore and refine immunotherapeutic strategies, the Oncology Immunotherapy market remains at the forefront of oncology, revolutionizing cancer treatment paradigms and offering new hope to patients.
This report aims to provide a comprehensive presentation of the global market for Oncology Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immunotherapy.
Report Scope
The Oncology Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Immunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Immunotherapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Immunotherapy Market Perspective (2019-2030)
2.2 Oncology Immunotherapy Growth Trends by Region
2.2.1 Global Oncology Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Immunotherapy Historic Market Size by Region (2019-2024)
2.2.3 Oncology Immunotherapy Forecasted Market Size by Region (2025-2030)
2.3 Oncology Immunotherapy Market Dynamics
2.3.1 Oncology Immunotherapy Industry Trends
2.3.2 Oncology Immunotherapy Market Drivers
2.3.3 Oncology Immunotherapy Market Challenges
2.3.4 Oncology Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Immunotherapy Players by Revenue
3.1.1 Global Top Oncology Immunotherapy Players by Revenue (2019-2024)
3.1.2 Global Oncology Immunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Immunotherapy Revenue
3.4 Global Oncology Immunotherapy Market Concentration Ratio
3.4.1 Global Oncology Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Immunotherapy Revenue in 2023
3.5 Oncology Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncology Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncology Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Immunotherapy Breakdown Data by Type
4.1 Global Oncology Immunotherapy Historic Market Size by Type (2019-2024)
4.2 Global Oncology Immunotherapy Forecasted Market Size by Type (2025-2030)
5 Oncology Immunotherapy Breakdown Data by Application
5.1 Global Oncology Immunotherapy Historic Market Size by Application (2019-2024)
5.2 Global Oncology Immunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Immunotherapy Market Size (2019-2030)
6.2 North America Oncology Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Immunotherapy Market Size by Country (2019-2024)
6.4 North America Oncology Immunotherapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Immunotherapy Market Size (2019-2030)
7.2 Europe Oncology Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Immunotherapy Market Size by Country (2019-2024)
7.4 Europe Oncology Immunotherapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Immunotherapy Market Size (2019-2030)
8.2 Asia-Pacific Oncology Immunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Immunotherapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Immunotherapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Immunotherapy Market Size (2019-2030)
9.2 Latin America Oncology Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Immunotherapy Market Size by Country (2019-2024)
9.4 Latin America Oncology Immunotherapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Immunotherapy Market Size (2019-2030)
10.2 Middle East & Africa Oncology Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Immunotherapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Immunotherapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Oncology Immunotherapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Oncology Immunotherapy Business (2019-2024)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck & Co
11.2.1 Merck & Co Company Detail
11.2.2 Merck & Co Business Overview
11.2.3 Merck & Co Oncology Immunotherapy Introduction
11.2.4 Merck & Co Revenue in Oncology Immunotherapy Business (2019-2024)
11.2.5 Merck & Co Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Detail
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Oncology Immunotherapy Introduction
11.3.4 Roche AG Revenue in Oncology Immunotherapy Business (2019-2024)
11.3.5 Roche AG Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Oncology Immunotherapy Introduction
11.4.4 AstraZeneca Revenue in Oncology Immunotherapy Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Detail
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Oncology Immunotherapy Introduction
11.5.4 Sanofi S.A. Revenue in Oncology Immunotherapy Business (2019-2024)
11.5.5 Sanofi S.A. Recent Development
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Detail
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Oncology Immunotherapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Oncology Immunotherapy Business (2019-2024)
11.6.5 Dendreon Pharmaceuticals Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Oncology Immunotherapy Introduction
11.7.4 Novartis Revenue in Oncology Immunotherapy Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Detail
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Oncology Immunotherapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Oncology Immunotherapy Business (2019-2024)
11.8.5 Gilead Sciences Inc. Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Oncology Immunotherapy Introduction
11.9.4 Merck KGaA Revenue in Oncology Immunotherapy Business (2019-2024)
11.9.5 Merck KGaA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’